Title: Patients with sickle cell disease presented dysregulated plasma Rb/K ratio and Gammaglutamyl cycle in red blood cells

Author (s): Shruti Bhatt¹, Amit Kumar Mohapatra², Apratim Sai Rajesh^{3,#}, Satyabrata Meher⁴, Pradip Kumar Panda⁵, Ranjan Kumar Nanda^{2*} and Suman Kundu^{1,6*}

- ¹Department of Biochemistry, University of Delhi South Campus, New Delhi 110021, India
- 8 ²Translational Health Group, International Centre for Genetic Engineering and Biotechnology, New
- 9 Delhi 110067, India

4

5 6

7

16 17

25

28 29 30

- ³Department of Biosciences and Biotechnology, Fakir Mohan University, Balasore 756019, India
- ⁴Multi-disciplinary Research Unit, Veer Surendra Sai Institute of Medical Science and Research, Burla,
- 12 Sambalpur, Odisha, 768017, India
- ⁵Sri Sri College of Ayurvedic Science and Research, Sri Sri University, Cuttack, Odisha 753015, India
- ⁶Department of Biological Sciences, Birla Institute of Technology and Science Pilani, K.K.Birla Goa
- 15 Campus, Goa 403726, India

*Correspondence:

- 18 Suman Kundu, BITS Pilani, K.K.Birla Goa Campus, Goa 403726 and University of Delhi South
- 19 Campus, New Delhi 110021, India;
- 20 Telephone No: +91-832-2580101
- 21 Email address: swundu@goa.bits-pilani.ac.in;
- 22 Ranjan Kumar Nanda, Translational Health Group, International Centre for Genetic Engineering and
- 23 Biotechnology, New Delhi 110067, India
- 24 Email address: ranjan@icgeb.res.in
- *Present affiliation: COVID-19 laboratory, Department of Microbiology, Veer Surendra Sai Institute of
 Medical Science and Research, Burla, Sambalpur, Odisha, 768017, India


Running title: RBC metabolome in sickle cell disease

Abstract

Patients suffering from sickle cell disease (SCD) present with multifactorial pathology, and a detailed understanding of it may help to develop novel therapeutics. In this study, the plasma elemental (²⁴Mg, ⁴⁴Ca, ⁵⁷Fe, ⁶³Cu, ⁶⁶Zn, ⁷⁷Se, ⁸⁵Rb, ²⁰⁸Pb, and ³⁹K) levels of SCD patients (n=10, male: 50%) and control groups (trait and healthy; n=10 each; male: 50%) were profiled using inductively coupled plasma mass spectrometry (ICP-MS). Additionally, comparative global erythrocyte metabolomics of SCD (n=5, male:100%) and healthy controls (n=5, male:100%) were carried out using liquid chromatography-mass spectrometry (LC-MS). SCD patients had higher plasma ²⁴Mg, ⁴⁴Ca, ⁶⁶Zn, ²⁰⁸Pb, and ³⁹K levels and lower levels of ⁵⁷Fe, ⁷⁷Se, and ⁸⁵Rb compared to controls. These changes in elemental levels, with a decreased Rb/K ratio in the SCD group, may explain the observed frequent hemolysis and severe dehydration with oxidative stress in patients. Mass spectrometry analysis of red blood cells (RBCs of SCD (n=5) and healthy controls (n=5) identified 442 unique metabolic features which separately clustered both the study groups in principal component analysis (PCA). A set of 136 features showed differential (p<0.05; log₂fold change>±1) regulation and was involved in Dglutamine/D-glutamate, sphingolipid, arginine biosynthesis, glutathione and glycine, serine and threonine metabolism. Interestingly, higher pyroglutamic acid levels were observed in the sickle shaped-RBCs indicating a perturbed gamma-glutamyl pathway in SCD patients. Supplementation of the depleted trace metals and targeting the perturbed metabolic pathways in the RBCs of SCD patients may provide avenues for the development of alternate therapeutics.

Key words: sickle cell disease; metabolomics; ionomics; red cells; oxidative stress; mass spectrometry.

Graphical abstract



1. Introduction

WHO has recognized sickle cell disease (SCD), the first known human molecular disorder, as a global health pandemic. SCD cases are predicted to increase from 300,000 to 400,000 by 2050 and the majority (2/3) of it was recorded in Africa and India [1-5]. SCD is caused by a genetic mutation that translates into the substitution of valine by glutamic acid, at the 6th position in the β chain of the hemoglobin molecule leading to a structural variant known as Hemoglobin S (HbS) [6-8]. HbS has a reduced oxygen affinity, and deoxygenation near tissues leads to exposure of hydrophobic sites on individual T-state HbS molecules [9].

Exposed hydrophobic sites act as a nucleus on the HbS molecule, aggregating and forming a 14 nm fiber leading to the sickle shaped RBCs (SS-RBCs). SS-RBCs block the blood vessels leading to an impaired blood supply to organs causing recurrent episodes of acute pain (vaso-occlusive crisis: VOC) and chronic damage leading to poor survival [10-14]. Understanding the detailed pathophysiology of SCD at the molecular and elemental level will be useful to identify targets for better clinical management [15].

Multi-omics studies using liquid chromatography and inductively coupled plasma mass spectrometry (LC-MS/ICP-MS) are useful to capture the metabolites and elemental details to better understand the disease pathophysiology. Several metabolomic studies have advanced our understanding of various disease pathobiology and have become backbone for the development of alternative therapeutics [16]. Metabolite profiling deciphered that enhanced ADORA2B signaling led to increased plasma adenosine levels, contributing to multiple SCDrelated complications [17]. It also captured an enhanced level of circulating sphingosine-1phosphate (S1P), a bioactive lipid, in both SCD mice and humans [18]. The Sphk1-led S1P increase reprogrammes the metabolic balance via the release of glycolytic enzymes in the cytosol [19], towards the Embden Meyerhoff pathway (EMP) rather than the Hexose monophosphate pathway (HMP) [20]. The metabolic switching induces sickling via elevated production of 2,3-BPG (2, 3 bisphosphoglycerate) [21], signals inflammation and tissue damage via the S1PR1 (S1P receptor 1) receptor on immune cells (myeloid lineage) [22]. A dysregulated Land's cycle, evident from increased lysophosphatidylcholine and arachidonic acid levels in SS-RBC, was reported using comparative blood metabolomic profiling of Sickle-Tg mice [23]. Interestingly, these few unbiased metabolic analyses have delivered a massive thrust to in-vitro, pharmacological, preclinical and human studies targeting the ADORA2B and SphK1-S1P-S1PR1-IL-6 signaling cascades to decipher alternative therapeutic strategies [24]. For example, PEG-ADA(adenosine deaminase deficiency), a clinically relevant drug used to treat ADA-deficient patients, reduced elevated adenosine levels, sickling, splenomegaly, multiple tissue damage, and pain [17]. Alternatively, a decrease in adenosine production can be achieved via CD73 inhibitor [e.g., adenosine 5'- $(\alpha,\beta$ -methylene) diphosphate], reduced sickling and multiple organ damage [25].

Similarly, a molecular antagonism of ADORA2B and SphK1 by PSB1115 and PF543, respectively, potently decreases sickling, inflammation and pain [26, 27]. However, only a fraction of these limited studies explored the metabolic profile of SS-RBCs derived from SCD patients [28-30]. Most have been performed on erythrocytes derived from cultured human RBCs and SCD-transgenic mice. Additionally, the previous studies fall short of capturing comprehensive pathological effects of sickle cell haplotypes including Senegal (SEN), Benin (BEN), Bantu or Central African Republic (CAR), Cameroon (CAM) and Arab-Indian (ARAB/AI) that represent the ethnic group or geographical region from which patients originated. To the best of our knowledge, no such investigation has been reported for Indian SCD diaspora. Thus, it would be interesting to investigate metabolic fingerprint of SS-RBCs (primarily Arab-Indian haplotype).

Furthermore, it has been repeatedly pressed that multi-omics can supplement and support pathophysiological understanding of various physiological stress [31]. Morphological, biochemical and metabolic changes/alterations induced by multiple pathological conditions can be correlated to the alterations in the concentration of elements in biofluids. The most notable example links RBC clearance with intracellular calcium levels [32, 33]. However, few studies establish the impact of stressors on the homeostatic loss of ions associated with SCD [34-36]. Inductively-coupled plasma mass spectrometry (ICP-MS) is a recent evolution of a decades-old analytical technique to measure elements at trace levels in biological fluids [37].

Thus, sparse and restricted reports on the perturbed metabolic pathways in RBCs and plasma elemental levels in SCD patients forged an exciting research avenue to be explored [29, 38-40]. In this study, a comparative plasma elemental composition was monitored between SCD and control (traits and healthy) groups and global RBC metabolome profiling between SCD and healthy controls was performed. This study provides an unique opportunity to integrate metabolomic and ionomic fingerprints to undertstand dysregulated metabolic pathways and identify markers associated with SCD. The lack of validated biomarkers for SCA severity represents a void in the state of knowledge of SCD that creates a critical roadblock in the design of clinical trials, the development of novel therapies and the emergence of precision medicine for SCD patients.

2. Materials and Methods

2.1 Ethics statement

163

164

165

166

167

168

169

170

171

172

173

174 175

176

177

178 179

180 181 182

183 184

185

186

187

188

196

197 198

199 200

201

202

203

204

205

206 207

208

209 210 All participants provided informed consent before participating in the study. This study was approved by the Institutional Ethics Committee of Sri Sri University, Cuttack, Odisha (SSCASRH/IEC/006/21) and University of Delhi South Campus, (UDSC/IEC/2021/Project/5.10.2021/4). The human studies reported in this study abide by the Declaration of Helsinki principles.

2.2 Study participants

189 For this study, blood samples were collected from a cohort of ten adult SCD patients with 190 hemoglobin SS (HbSS, n=10, male 50%) disease (Supplementary Table S1), sickle cell trait 191 individuals (hemoglobin AS: HbAS, n=10, male 50%) and ten healthy adults (controls, HC, 192 n=10, male 50%). Written informed consent was obtained from all patients and controls. All 193 protocols and procedures were approved by institutional ethics committees of the collaborating 194 institutes handling patient samples. 195

2.3 Sample collection and processing

For this study, blood samples were collected from SCD patients in EDTA with hemoglobin SS disease and healthy adults (controls). Complete blood count (CBC) determined the clinical profile of participants; cellulose electrophoresis, PCR, and HPLC are presented in Supplementary Tables 1 and 2. The participants were enrolled according to the approved inclusion and exclusion criteria with consent (S.1.2). The inclusion criteria were a confirmed diagnosis of sickle cell disease by HPLC. Individuals who had received a transfusion were excluded from the study. All patients were receiving analgesic treatments. Blood samples, taken from patients with SCD, were characterized by their sickling properties [41]. Blood tubes were then centrifuged at 2000 ×g for 10 min to separate the RBCs and plasma and were aliquoted into equal volumes (0.5 ml). Plasma samples were stored in a -80 °C freezer until analysis. Samples were processed according to a biphasic liquid-liquid extraction (LLE) protocol. Briefly, RBC metabolism was quenched by extracting metabolites into methanol/water/chloroform solvents.

2.3.1 Untargeted metabolite profiling of sickle RBCs

The 0.5 ml aliquots of human donor erythrocytes (Sri Sri University) that had been pre-treated 211 with heparin anti-coagulant were placed in 2.0 ml microcentrifuge tubes (MCT). After adding 212

- internal standards, they were centrifuged at 1000 ×g and 4 °C for 2 min and then placed on ice
- while the supernatant was aspirated. The RBCs were washed twice with their resuspension in
- 215 1x phosphate-buffered saline (PBS) through centrifugation, and finally the supernatant was
- aspirated to leave an RBC pellet. These wash cycles remove non-erythrocytic metabolites and
- other compounds that may still be present outside the cells; however, it also delays quenching,
- and might leave residual traces of phosphate salts.

2.3.2 Metabolite extraction

219

239

- To the RBC pellet of each tube, 0.15 mL of ice-cold, ultrapure water (Milli-Q Millipore,
- 221 Mississauga, Canada) was added to resuspend the erythrocytes. The tubes were first plunged
- into the dry ice for 30 seconds followed by 20 seconds of incubation in the water bath at 37 °C
- 223 to quench metabolism and lyse the cells. After quenching with dry ice, 0.6 ml of methanol at
- 224 20 °C temperature was added, and the tubes were then vortexed to ensure complete mixing.
- The tubes were then plunged again into dry ice where 0.45 ml of chloroform was added to each
- tube. These tubes were vortexed briefly every 5 min for 30 min, and between each brief
- vortexing interval, they were placed in a cold bath. After 6 brief vortexes, the tubes were
- transferred to room temperature and 0.15 ml of ice-cold, ultrapure water (Milli-Q Millipore,
- 229 Mississauga, Canada) was added to drive the phase separation between methanol and
- chloroform. The tubes were centrifuged at 1,000 ×g for 2 min at 4 °C so that a clear separation
- of the two phases could be observed above and below the compact disk of erythrocytes. After
- centrifugation, the tubes were transferred to a -20 °C freezer for an overnight incubation to
- allow residual chloroform to precipitate out of the aqueous methanol phase. The two liquid
- phases in each tube were transferred to separate 1.5 mL microcentrifuge tubes without
- disturbing the compact disk of erythrocytes or transferring any erythrocytes to the new tubes.
- The final volumes translated to a methanol/water/chloroform ratio of 4:2:3 for extraction and
- phase separation. The samples were then dried with speed-vac and resuspended in 0.2 mL LC
- mobile phase (97.9% ultra-pure water / 2% acetonitrile / 0.1% formic acid) [42].

2.3.3 UPLC-Q-Exactive Plus Orbitrap MS/MS analysis

- All the samples were analyzed using an UHPLC system (UHPLC Dionex UltiMate® 3000,
- 241 Dionex, Thermo Fisher Scientific, United States) that was controlled with Thermo Xcalibur
- software (Thermo Fisher Scientific, United States). The samples were separated using a
- 243 Kinetex UPLC C18 column (100 × 2.1 mm, 1.9 μm; Phenomenex, Torrance, CA, United
- States). The mobile phase consisted of solvent A (0.1% formic acid) and solvent B (acetonitrile
- with 0.1% formic acid). Gradient elution was applied using the following optimized gradient
- program: A 35-min gradient at a flow rate of 0.3 ml/min with the following conditions was
- used for separation: 0–5 min, 1% B; 5–10 min, linear gradient from 1–3% B; 10–18 min, linear
- gradient from 3-40% B; 18-22 min, linear gradient from 40-80% B; 22-27 min, column
- cleaning at 95% B; and 27–35 min, re-equilibration at 1% B.
- 250 Mass spectrometry was performed on a Q-Exactive PlusTM Quadrupole-Orbitrap mass
- 251 spectrometer (Thermo Fisher Scientific, United States) in positive ion mode. Data-dependent
- acquisition method was used for MS/MS of small molecules in the extractions. The complete
- 253 MS settings were 70,000 resolution, 1e⁶ AGC (Automatic Gain Control), 100 ms max inject
- time, and 100–1500 m/z. The MS/MS settings were 35,000 resolution, 1e5 AGC, 100 ms max
- inject time, 1.0 m/z isolation window, and 30 dynamic exclusions. Three technical replicates
- were run for each extraction, and each technical replicate used a different HCD collision energy
- 257 (25, 30, and 35, respectively).
- 258 Compound DiscovererTM 3.0 (Thermo Fisher Scientific, United States) software was used to
- analyze the LC-MS/MS data for each extraction in positive ion mode.
- 260 Data normalization and analysis were carried out using MetaboAnalyst 5.0
- 261 (www.metaboanalyst.ca) [43]. Data exclusion was performed for metabolites with constant
- values across metabolites and interquartile filtering. Missing values were mean imputed, and

normalization was performed. For univariate analysis, fold change and T-test values were calculated, followed by multiple testing correction based on false discovery rate (FDR). ROCcurve (receiver operating characteristic) analysis was also carried out for each metabolic feature, and 95% confidence intervals were calculated using bootstrapping with 1000 permutations. Multivariate exploratory analysis was performed using principal component analysis (PCA) and orthogonal projections to latent structures discriminant analysis (OPLS-DA). Permutation testing for OPLS-DA was applied to evaluate model stability to parameter addition. Linear support vector machine (SVM) classifiers were built to predict group class using Monte-Carlo cross-validation (MCCV) and balanced subsampling. A total of six SVMs with an increasing number of metabolites (maximum 100) were compared. Model evaluation was performed using ROC curves, and biomarker identification was achieved using the feature ranking method implemented in SVM (S.2.2, Fig. S3a, b, c).

2.4 Trace metal quantification using inductively coupled plasma mass spectrometry (ICP-MS)

Plasma samples of study groups were processed and subjected to ICP-MS to quantify ²⁴Mg, ⁴⁴Ca, ⁵⁷Fe, ⁶³Cu, ⁶⁶Zn, ⁷⁷Se, ⁸⁵Rb, ²⁰⁸Pb, and ³⁹K. Plasma samples (100 μl) were transferred to MG5 vials (Anton Paar, Graz, Austria), and HNO₃ (250µl, 70%, #225711 Sigma Aldrich, St. Louis, Missouri, United States, with ≥99.999% trace metal basis) and H₂O₂ (50µl, 30%, 231 #1.07298.1000, Supelco, Inc. Bellefonte, Pennsylvania, USA) were added. Vials were sealed using sealers (#411860, Anton Paar). The vials containing the reaction mixtures were digested using a microwave digestion system (Anton Paar, Graz, Austria) ramped up to 300 W in 15 min, where it was held for 10 min. The digested samples diluted using trace metal-free water spectrometry (ICP-MS) $M\Omega \times cm$) for inductively coupled plasma mass analysis. Digested samples were analyzed using ICP-MS (iCAPTM TQ ICP-MS, Thermo Scientific, USA). Thermo Scientific Otegra Intelligent Scientific Data Solution (ISDS) software was used for operating and controlling the instrument. The ICP-MS was calibrated using a multi-element standard mix (#92091, Sigma Aldrich, St. Louis, Missouri, United States) prepared in 1% HNO₃ per the manufacturer's instruction. Calibration plots were prepared at 1 ppb to 5 ppm concentrations and showed R²= 0.99. Digested samples were aspirated using a V-grooved MicroMist DC nebulizer and spray chamber of ICP-MS using a sample capillary (0.55 mm). Samples were then passed through a quartz torch with an injector having a diameter of 2 mm. Here, plasma ionized samples passes through sample cones, followed by a skimmer cone. The experiments were conducted in KED (Kinetic energy dissociation) mode to avoid any polyatomic ion interference. During the run, the nebulizer flow was set at 1.04 l/min with a pressure of 3.20 bar. The peristaltic pump revolved clockwise at 40 rpm. The quartz torch produced plasma and the exhaust was maintained at 0.49 mbar. Interface temperature was maintained at 29.98°C with a N₂ flow of 14 l/min. The system's sample and skimmer cones were made of nickel with orifices of 1 mm and 0.5 mm, respectively. Between sample runs, HNO₃ (1%) was pumped through the nebulizer with a wash-out time of 30 sec to remove any carryover. The complete experiment was carried out with a dwell time of 0.1s. The average of three runs for each element concentration was calculated and exported for further statistical analysis. Comparative trace element levels between study groups (HbSS, HbAS and HbAA) were calculated considering the limit of detection and dilution factors.

2.4.1 Statistical analysis

263

264

265

266

267

268

269

270

271

272

273

274275

276

277

278

279

280

281 282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297 298

299

300 301

302

303

304

305

306 307

308

An unpaired t-test was performed using Graphpad prism 8 to identify group-specific variations and a p<0.05 was selected as significant.

3. Results

313314

315

316

317

318

319320321

322

323

324 325

326

327

328 329

330 331 332

333

334335

336

337

338

339

340

341

342

343

344

345

346

347348

349

350

351

352

353

354

355

356357

358 359 360

361

362

3.1 Clinical characteristics of the study participants

In this case and control study, a total of 30 study participants belonging to SCD as case and control (sickle cell trait and healthy controls) were used for plasma ionomic and RBC metabolomic profiling. The demographic and clinical characteristics of study participants are presented in Supplementary Tables S1 and S2.

3.2 Sickle cell anemia is associated with an altered ionomic profile

From the comparative plasma trace element analysis, significantly higher plasma levels of Mg (p<0.0001), Zn (p<0.0001), Ca (p<0.01), Pb (p<0.01), and K (p<0.01) were observed in SCD patients compared to healthy controls (Fig. 1a, c, d, e, h). Significantly lower plasma levels of Fe, Se (p<0.05), and Rb (p<0.01) were observed, indicating higher oxidative stress in SCD patients (Fig. 1b, g and i). However, Cu levels were similar between study groups (Fig. 1f). Overall, the subjects with sickle cell trait had comparable trace metal levels to the healthy controls except for Rb whose levels hovered in between the levels observed in SCD and healthy control (Fig. 1i). We found that there was a steady decrease in Rb/K levels in the SCD group compared to the healthy controls (Fig. 1j)

3.3 Metabolomics profiling of RBCs of patients with SCD demonstrated significant deregulation of specific metabolites compared to the healthy controls.

Global metabolomic profiling of RBCs from SCD patients and healthy donors yielded 442 metabolite features. Principal Components Analysis (PCA) analysis of these analytes showed separate non-overlapping clusters of SCD and healthy groups. The principal components 1 and 2 explained 44.2% of the total variance (Fig. 2a). A supervised OPLS-DA model was evaluated to identify significant differentially abundant metabolites between groups and validated using permutation tests (Fig. S2a). A random permutation test (n = 2000) resulted in an interpretation rate (R₂) and prediction ability (Q₂) of 0.999 and 0.891, respectively (Fig. S2b). A set of 10 analytes (S.2.2, Fig. S2c) qualified the variable importance in projection (VIP) scores >1.0 and were identified as important metabolites. These metabolites displayed significantly different concentrations between groups, with fold changes >1.0 or <0.5. In the univariate analysis, 136 showed differential expression (62/56; up-/down-regulated; FC>; p<0.005) in SCD (Fig. 2b, Table S3 and Table S4). After false discovery rate adjustment, 18 analytes (7/10; up/down regulated) showed significant deregulation. In the RBC of SCD patients, glutathione, aminolevulinic acid, DL-2-aminooctanoic acid, D-glutamine, and aminoadipic acid (Table S3) levels were significantly high. Significantly lower levels of N6,N6,N6-trimethyl-L-lysine, dihydrothymine, pyroglutamic acid, 2'-alpha-mannosyl-L-tryptophan and 2-aminoisobutyric acid were observed in the RBC of the SCD patients compared to healthy controls (Fig. 2b, 2c). Hierarchical clustering analysis was performed to identify top 25 significantly dysregulated metabolic features in SCD and healthy control (Fig. 2c). The SVM model evaluation highlighted the common metabolic features (Fig. S3c) with the OPLS-DA (Fig. S2c) and hierarchical clustering analysis (Fig. 2c), i.e., thiazolidine-4-carboxylic acid, N-[(3-exo)-8-Benzyl-8-azabicyclo[3.2.1]oct-3-yl]-2-methylpropanamide, ethyl-3-phenylpropionate, meprobamate, N-BOC hydroxylamine. Interestingly, amongst the common metabolic features, thiazolidine-4-carboxylic acid and its derivatives have been reported reduce oxidative stress induced cell death [44].

3.4 Functional pathway analysis

The significantly dysregulated metabolites in SCD group were selected for the KEGG pathway analysis using MetaboAnalayst (https://www.metaboanalyst.ca). D-glutamine and D-

glutamate metabolism (p-value = 0.0006, Fig. S6a), aminoacyl-tRNA biosynthesis metabolism (p-value = 0.0009), sphingolipid metabolism (p-value = 0.0009), arginine biosynthesis (p-value = 0.00099), glycine, serine and threonine metabolism (p-value = 0.004, Fig. S6b), beta-alanine metabolism (p<0.005), arginine and proline metabolism (p<0.007), glutathione metabolism (p<0.009, Fig. S6c), glutathione metabolism (p<0.01), and ether lipid metabolism (p<0.012) were significantly altered in the RBC of SCD patients compared to the control group (Fig. 2d).

4. Discussion

 The overwhelming significance of RBCs stems from the enormous abundance of hemoglobin. Any alteration in structural and functional attributes of hemoglobin can translate into irregularities in RBC functions. These irregularities can have different clinical complications




Figure 1. Plasma trace element levels of sickle cell patient (HbSS), sickle cell trait (HbAS) and healthy control (HC) and their ratio showed significant differences. a) Mg, b) Fe, c) Ca, d) Zn, e) Pb, f) Cu, g) Rb, h) K, i) Se, j) Rb:K. *p < 0.05, **p < 0.01, ****p < 0.001 ***** p <0.0001; HbSS: Sickle cell disease; HbAS: Sickle cell trait; HC: Healthy control.

inside the human body [45-47]. The RBCs are designated as a simple model to study cellular mechanisms due to less epigenetic, transcriptional and translational complications to regulate the cross-talk amongst various pathways [48-50]. However, recent omics studies highlight the existence of a complex network of cytosolic enzymes which regulate the energetics and functioning of RBCs [51, 52]. Physical and pathological stresses can alter the metabolic equilibrium and accelerate disease progression. Thus, an in-depth understanding is required to deconstruct the highly interlinked stressed RBC pathophysiology [53].

Enhanced hemolysis observed in SCD patients might be contributing to the observed higher plasma Mg level (p<0.001) [54]. This finding is in agreement with observations by Olukoga, A. O et al. (1990) [55] which establishes a negative correlation between erythrocyte and plasma Mg in the SCD cohort [56]. In contrast, low serum Mg levels have been reported in SCD patients due to Mg homeostasis [57, 58].




Figure 2. Pertubed RBC metabolic fingerprint observed in sickle cell disease patients (HbSS) compared to the healthy control (HC). a) PCA score plot showed RBC metabolites (n=442) of SCD patients cluster away from the healthy controls. b) Volcano plot highlighting the dysregulated erythrocyte metabolites in SCD (HbSS) compared to the healthy control (HC). c) Hierarchical Clustering representing the distribution of 25 important RBC metabolites in SCD patients and healthy

controls. Columns correspond to samples, and rows to individual metabolites. The color scale indicates the relative abundance of metabolites: red being the most abundant and blue the less abundant metabolites. d) Metabolic pathways altered in the RBCs of SCD patients compared to healthy controls. The pathway impact values (x-axis) represent the influencing factor of topological analysis, and the $-\log(p)$ (y-axis) represents the p-value of the pathway enrichment analysis. The vital metabolic pathways were defined as having $-\log(p) > 2$ and pathway impact factor > 0.2.

Similarly, RBCs contain 10-15% of the total cellular pool of calcium. Sickle cells show increased Ca as compared to normal cells in the oxygenated state [59]. Malinovská V et al. (1991) reported that stress conditions increase plasma Ca levels [60]. Higher plasma Ca levels as observed in SCD patients can be attributed to frequent hemolysis due to prolonged stress in SCD patients [61]. However, in SCD an accumulation of intraerythrocytic Ca has been reported due to malfunction of Ca²⁺ transporters [33]. Higher plasma Ca levels as observed in SCD patients can be attributed to frequent hemolysis due to prolonged stress in SCD patients [62]. An increased intracellular Ca concentration induces alteration to calcium-sensitive potassium (K⁺) channel protein 4 (also known as the putative Gardos channel and K–Cl cotransporter 1 (KCC1), KCC3 and/or KCC4 [63], resulting in potassium-efflux and decreased cell volume [64-66], which in turn increases the stiffness of RBC. Similarly, we also observed higher plasma K levels corroborating earlier reports [67-71]. Thus, K⁺ is an important indicator of SCD, however, its measurement to assess the severity in many pathophysiological conditions can be erroneous due to factors like pseudohyperkalemia and poses a challenge [72].

Another similar group I alkali metal, rubidium (Rb⁺) was significantly lower (p<0.01) in SCD patients compared to the trait and control group. It shares similar biochemical properties and readily exchanges with K⁺ and thus, can be a useful proxy for K⁺. Although its biological function still needs further understanding, ⁸⁶Rb's prominent presence was utilised to measure basal metabolic rate, establishing a correlation between its radioactive turnover and K⁺ concentration [73]. We are the first to report a correlation between plasma Rb and K⁺ concentration, which significantly decreased from healthy to trait and even decreased further in the SCD group. Rb may have the potential to be used as a marker to assess the severity associated with sickling. Rb has unique neurophysiological and neuroprotective properties [74-76]. Kordjazy et al. (2015) found that mice administered with Rb showed less depression-like behaviour through changes in the hippocampus [77]. Recent clinical trials and studies have widely reported that SCD patients suffer from neuro-cognitive complications [78-80]. Neurocognitive impairment have been reported in children with SCD, which affects their visuo-spatial memory(14.8%), IQ (85.4%) and copying (68.2%) [79, 81, 82]. These studies indicate that SCD can lead to the development of neuro-complications. Thus, Rb's beneficial role in improving SCD patients' neurocognitive complications can be further explored.

We observed significantly higher plasma lead levels in SCD compared to the trait and healthy cohort. These findings align with previous studies that have correlated BLL (Blood lead level) levels with moderate and severe anemia [83]. In addition to neurological toxicity, Pb can worsen sickle cell anemia by impairing heme synthesis and increasing the rate of red blood cell destruction [84]. Schwartz et al (1982) showed a dose-dependent increase in anemia in children with blood lead levels near 25 μ g/dl [83, 85]. A linear decrease in hemoglobin was reported in children with increased BLL (BLL >30 μ g/dl) by Drossos et al (1985) [86]. Although these findings indicate a relationship between Pb levels and SCD, a more detailed analysis is required to solidify these claims.

High plasma Zn levels of the SCD group was observed compared to trait and control group that does not corroborate with earlier reports [34, 87]. An increased iron (Fe) concentration in the intestinal lumen may antagonize the uptake of Zn [88]. Zn concentrations have been inversely correlated to Copper (Cu) levels [87, 89]. This depletion of Cu could impair iron absorption [90]. However, no such relationship was observed in our present study

and no significant change in Cu levels was observed across the group. On the contrary, a steady Fe increase was observed in trait and healthy group (p<0.05), which indicates disrupted Fe homeostasis and most often caused by excessive urinary loss of iron as reported by some studies [91, 92].

474 475

476

477

478

479

480

481

482

483

484

485 486

487

488

489 490

491

492 493

494 495

496

497

498 499

500

501

502

503 504

505

506

507

508 509

510

511

512

513

514

515

516

517

518

519

520 521

522

523

Selenium (Se) is an essential component of mammalian enzymes like glutathione peroxidases (GPx) [93, 94], providing antioxidant defence against ROS. Erythrocytes of Sedeficient rats failed to protect hemoglobin from oxidative damage in the presence of ascorbate or H_2O_2 or glutathione [94]. Se deficiency is known to alter erythroid parameters like RBC, HCT, HGB, and MCHC (P < 0.05) and makes erythrocytes osmotically fragile [95]. The family is involved in oxido-reduction reactions and these reactions occur in diverse tissues and physiological pathways. Se supplementation has preventive and therapeutic role in diverse disease conditions [96-100]. Plasma Se levels were highest in the healthy and lowest in the SCD group (p < 0.05); so Se supplementation may be beneficial to SCD patients.

4.1 Metabolic insights in sickle RBCs indicate an altered Gamma-Glutamyl cycle which fuels ATP depletion from sickle red blood cells

The main oxidative damage control system in RBCs, the glutathione pathway, has been reported to be altered in HbS red blood cells [101]. There is increasing evidence that this alteration leads to oxidative stress with a negative domino effect on the pathophysiology of SCD [61]. ROS can be derived non-enzymatically (Fenton chemistry) from denatured sickle hemoglobin (Hb S) moieties and lipid peroxidation or derived enzymatically by the action of NADPH oxidase. ROS damage RBC membranes and decrease cell deformability, which contributes to the pathophysiology of SCD [102]. Plasma-free hemoglobin (Hb) and iron chelates are by-products of hemolysis that can also act as oxidants [103]. To counteract ROS, mammalian cells have antioxidant pathways involving reduced glutathione (GSH), NAD(H), NADP(H), glutamine and nitric oxide (NO), which are complex and interlinked. Glutathione exists in a reduced (GSH) and oxidized (GSSG) form. The thiol reductant, GSH, scavenges ROS such as hydrogen peroxide and lipid peroxides [103, 104]. GSH can also interact with Hb to form glutathiol-hemoglobin (G-Hb) which reduces the propensity for sickling [105]. Similarly, we observed alterations in glutathione pathway along with disruptions in glutamine/glutamate metabolism, which are the main oxidative damages control system in RBCs of HbS cells.

Significant disruptions in glycine, serine, and threonine metabolism with lower 5aminolevulinate levels (p-value<0.01), which is a by-product of glycine, indicate lower glycine levels (Fig. 3, Fig. S6c). Chronic oxidative stress leads to increased GSSG efflux that exceeds the rate of GSH synthesis [106]. However, rapid efflux of GSSG leads to NADPH depletion, which was observed in our study. Thus, de novo GSH synthesis becomes critical in these oxidative stress conditions and needs glycine, glutamate, and cysteine in an ATP-dependent biosynthesis. Catabolism of GSH via membrane mounted gamma-glutamyl transpeptidase (GGT) followed by removal of gamma-glutamyl moiety from GSH by gamma-glutamyl transpeptidase yields cysteinyl-glycine conjugates (Cys-Gly) and g-glutamyl-amino acid (G-Glu) as products. Hydrolysis of these conjugates by ectoprotein dipeptidases (DPT) yields cysteine and glycine. The g-Glu, glycine and cysteine enter the cell through specific transporters. The g-glutamyl with an amino acid derivative enters the cell and gamma-glutamyl cyclotransferase (y-GCT/GGCT) converts to 5-oxoproline and the corresponding amino acid. 5-oxoprolinase (OXP) coverts 5-oxoproline (pyroglutamic acid) to glutamate in a ATP dependent manner. Oxoproline is converted to a dipeptide i.e. g-glutamylcysteine by combining glutamate and cysteine by gamma-glutamylcysteine synthetase (γ-GCS/G-GCS) in a two-step reaction which utilizes an ATP per catalytic step. This g-glutamyl cysteine can either act as substrate for GGCT to recycle to 5-oxoproline or it can be converted to GSH by the addition of glycine through GSH sythetase (GS) activity with the usage of an ATP molecule [106-108].

ATP production and antioxidant systems within the RBC exploit Hb-based O₂-transport to respond to various physiologic and pathophysiologic stresses. RBCs produce energy through the hexose monophosphate pathway (HMP) and glycolysis, only via the Embden-Meyerhof pathway (EMP), which generates ATP [109]. The HMP route produces NADPH, which powers the thiol-based antioxidant system critical for maintaining homeostasis in the O₂-rich RBC [110]. For example, O₂ offloading promotes glycolysis to generate both 2,3-BPG (a negative allosteric effector of Hb O₂ binding) and ATP. Dynamic regulation of ATP ensures the functional activity of ion pumps, cellular flexibility, drives metabolic reactions and vaso regulation/dilation under hypoxic stress (Fig. 3). A toggle between frequency of EMP and HMP is regulated by the assembly of an EMP protein complex upon the cytoplasmic domain of the band 3 membrane protein [cdB3, also known as anion exchanger 1 (AE1)] [111-118]. Metabolite flux through EMP vs. HMP oscillates depending on the Hb conformation (oxygenation state) and cdB3 phosphorylation. RBC deoxygenation promotes the generation of ATP, while full oxygenation of RBCs promotes NADPH generation [109, 119]. Rogers and co-workers (2009) showed that RBC antioxidant systems fail when HMP flux is blunted by altered cdB3 protein assembly/phosphorylation caused by aberrant Hbs or hypoxia [109, 120,

SS-RBCs are characterized by elevated indices of oxidative stress and depressed ATP levels[122], as well as elevated 2,3-DPG. Recently published evidence suggests a role for pannexin 1 (Px1) in the release of ATP from RBCs due to Gi protein stimulation in SCD [123, 124]. Zhang et al. (2011) showed that an elevated level of plasma adenosine plays a role in the increased concentration of DPG, which contributes to SCD pathophysiology by decreasing O₂ affinity, which in successive turn promotes HbS polymerization, RBC sickling, and hemolysis [125]. As a consequence, the hydrolysis of extracellular ATP and accumulation of adenosine are favoured, and signalling via adenosine receptors may promote deoxygenation of sickle Hb and in turn (HbS) polymerization and RBC sickling.

The higher levels of pyroglutamic acid or 5-oxoproline in SS-RBCs compared to healthy counterparts can be attributed to an anomaly in salvage pathway of GSH (Fig. S6a, b). 5-oxoproline is acted upon by the 5-oxoprolinase enzyme (ATP-requiring enzyme) to yield glutamate [126]. The conversion of glutamate by the action of two consecutive ATP-dependant enzymes yields back GSH (Fig. 3). However, 5-oxoprolinase exhibited slow and inefficient enzyme activity (reaction rate of 0.45 nmol/h), which may explain the increased levels of 5-oxoproline in the cells[127]. Also, if γ -GCS fails to find an acceptor cysteine during its catalysis, it can autocyclize γ -glutamyl phosphate (intermediate product) to form 5-oxoproline [128].

Furthermore, a depleted pool of ATP, cysteine, and glycine due to sickle pathophysiology as discussed above can retard the activity γ -glutamyl cycle enzymes, i.e., OXP, γ -GCS and GS[129]. Bacchawat et al., proposed a similar futile cycle involving ATP-dependant γ -glutamyl cycle enzymes like γ -GCS and 5-oxoprolinase, leading to rapid depletion of ATP in cystinosis cells per cycle [130].

Alternatively, we can also hypothesize an abnormal activity of GGCT enzyme that leads to the accumulation of 5-oxoproline by acting on g-glutamyl-AA as a response to a decline in the concentration of cellular GSH under oxidative stress. Previous reports showed that GGCT reduces oxidative and osmotic stress in RBCs which prevents deformability prolonging their life span [131]. In various cancers, higher GGCT expression was observed and reported as a therapeutic target [132]. In SS-RBCs, a deregulated GGCT response leads to ATP depletion and also limits the availability of glycine and cysteine, which are GSH precursors [132].

5. Conclusion

In this study, we reported an altered elemental profile of plasma from sickle cell patients and healthy controls. We observed higher levels of Mg, Zn, Ca, K, and Pb in the plasma of SCD compared to the control groups which corroborated with frequent hemolysis, rampant dehydration of SS-RBCs via ion loss through the Gardos channel (due to K^+ loss), and anemia-induced lead accumulation. Additionally, a steady decrease in plasma Rb/K ratio was observed for SCD when compared to trait and healthy control. We found that compromised functioning of γ -glutamyl cycle leading to high levels of oxidative stress was associated with SCD. These data could be validated in a larger population while taking other clinical parameters into consideration. This will be useful to gain deeper insight into the biomechanical breakdown of SS-RBCs at the molecular level and critical for identifying novel therapeutic targets for SCD patients.




Figure 3. Schematics outlining the biomechanical aberration and oxidative stress leading to inoperable γ -glutamyl cycle in SS-RBCs. Metabolites in shades of yellow are increased in SS-RBCs compared to healthy. Metabolites in shades of blue are decreased in SS-RBCs compared to healthy. Increase in color intensity indicates a higher magnitude. The solid red arrows indicate an altered gammaglutamyl cycle; the yellow arrow depicts altered GSH redox cycle; arrows with dashed outline entails an obstructed metabolic reaction; green arrows/text depicts previously reported pathophysiology of SS-RBCs. GGCT: gamma-glutamyl cyclotransferase; GGT: gamma-glutamyltranspeptidase; γ -GCS: glutamate cysteine ligase; GS: glutathione synthase; OXP: 5-oxoprolinase; γ -Glu-Cys-Gly: glutathione; DP: dipeptidase; HMP: hexose monophosphate pathway; EMP: Embden Meyerhof pathway; ATP: Adenosine triphosphate; ADP: Adenosine diphosphate; AMP: Adenosine monophosphate; Pi: phosphate.

Funding information

SK acknowledges financial support from the University of Delhi (Institution of Eminence grant IOE/FRP/LS/2020/27). SK also acknowledges the financial support from BITS Pilani, K.K. Birla Goa campus (BPGC/RIG/2022-23/09-2022/01; GOA/ACG/2022-2023/Oct/10). RKN acknowledges Core support from the ICGEB New Delhi Component and project support from Department of Biotechnology New Delhi. SB acknowledges Department of Biotechnology, Government of India for Research Fellowship. ASR is thankful to the Government of Odisha for the Biju Patnaik Research Fellowship.

Author contributions

- Shruti Bhatt: Ideated the study, processed samples, designed and performed the ionomic and
- 612 metabolomic experiments, analysed and plotted data, prepared the draft of the manuscript.
- Amit Kumar Mohapatra: Performed ionomic experiments, analysed ionomics data, helped in drafting the manuscript
- Satyabrata Meher, Apratim Sai Rajesh and Pradip Kumar Panda: Recruitment of participants,
- clinical profiling, human sample collection, processing and transport
- Ranjan Kumar Nanda and Suman Kundu: Conceived and supervised the study, analysed data,
- provided tools and reagents, raised funds and drafted and edited the manuscript.

Conflicts of interest

The authors declare no conflict of interest.

Acknowledgement

Prof. Alo Nag, Department of Biochemistry, University of Delhi South Campus, New Delhi, India, is acknowledged for administrative supervision and scientific discussion with SB. Prof. Bishnu Prasad Dash, Adjunct Professor, ICMR-Regional Medical Reasearch Centre, Bhubaneshwar, Odisha, India is acknowledged for scientific discussion with SB and ASR. Ms. Nidhi Mittal is acknowledged for scientific discussions with SB. Central Instrumentation Facility (CIF), University of Delhi South Campus, New Delhi, India, is appreciated for help with metabolomics data collection. Mr Anil Bhansali, Sai Phytoceuticals, New Delhi is appreciated for inspiring the laboratory to investigate sickle cell disease. Dharmender Singh is acknowledged for miscellaneous help to the laboratory.

Figure Legends

- Figure 1. Plasma trace element levels of sickle cell patient (HbSS), sickle cell trait (HbAS) and healthy control (HC) and their ratio showed significant differences. a) Mg, b) Fe, c) Ca, d) Zn, e) Pb, f) Cu, g) Rb, h) K, i) Se, j) Rb:K. *p < 0.05, **p < 0.01, ***p < 0.001 **** p < 0.0001; HbSS: Sickle cell disease; HbAS: Sickle cell trait; HC: Healthy control.
 - Figure 2. Pertubed RBC metabolic fingerprint observed in sickle cell disease patients (HbSS) compared to the healthy control (HC). a) PCA score plot showed RBC metabolites (n=442) of SCD patients cluster away from the healthy controls. b) Volcano plot highlighting the dysregulated erythrocyte metabolites in SCD (HbSS) compared to the healthy control (HC). c) Hierarchical Clustering representing the distribution of 25 important RBC metabolites in SCD patients and healthy controls. Columns correspond to samples, and rows to individual metabolites. The color scale indicates the relative abundance of metabolites: red being the most abundant and blue the less abundant metabolites. d) Metabolic pathways altered in the RBCs of SCD patients compared to healthy controls. The pathway impact values (x-axis) represent the influencing factor of topological analysis, and the $-\log(p)$ (y-axis) represents the p-value of the pathway enrichment analysis. The vital metabolic pathways were defined as having $-\log(p) > 2$ and pathway impact factor > 0.2.
 - Figure 3. Schematics outlining the biomechanical aberration and oxidative stress leading to inoperable γ-glutamyl cycle in SS-RBCs. Metabolites in shades of yellow are increased in SS-RBCs compared to healthy. Metabolites in shades of blue are decreased in SS-RBCs compared to healthy. Increase in color intensity indicates a higher magnitude. The solid red arrows indicate an altered gamma-glutamyl cycle; the yellow arrow depicts altered GSH redox cycle; arrows with dashed outline entails an obstructed metabolic reaction; green arrows/text depicts previously reported pathophysiology of SS-RBCs.
 - GGCT: gamma-glutamyl cyclotransferase; GGT: gamma-glutamyltranspeptidase; γ -GCS: glutamate cysteine ligase; GS: glutathione synthase; OXP: 5-oxoprolinase; γ -Glu-Cys-Gly: glutathione; DP: dipeptidase; HMP: hexose monophosphate pathway; EMP: Embden Meyerhof pathway; ATP: Adenosine triphosphate; ADP: Adenosine diphosphate; AMP: Adenosine monophosphate; Pi: phosphate.

710 References

- 712 [1] L. Pauling, H.A. Itano, et al., Sickle cell anemia a molecular disease, Science 110(2865) (1949) 543-713 8.
- 714 [2] S.A. Pereira, S. Brener, C.S. Cardoso, A.B. Proietti, Sickle Cell Disease: quality of life in patients with
- hemoglobin SS and SC disorders, Rev Bras Hematol Hemoter 35(5) (2013) 325-31.
- 716 [3] F.B. Piel, [Sickle-cell disease: geographical distribution and population estimates], Med Sci (Paris)
- 717 29(11) (2013) 965-7.

- 718 [4] F.B. Piel, M.H. Steinberg, D.C. Rees, Sickle Cell Disease, N Engl J Med 376(16) (2017) 1561-1573.
- 719 [5] F.B. Piel, T.N. Williams, Subphenotypes of sickle cell disease in Africa, Blood 130(20) (2017) 2157-720 2158.
- 721 [6] D.C. Rees, T.N. Williams, M.T. Gladwin, Sickle-cell disease, Lancet 376(9757) (2010) 2018-31.
- 722 [7] M.K. Safo, O. Abdulmalik, R. Danso-Danquah, J.C. Burnett, S. Nokuri, G.S. Joshi, F.N. Musayev, T.
- Asakura, D.J. Abraham, Structural basis for the potent antisickling effect of a novel class of five-
- membered heterocyclic aldehydic compounds, J Med Chem 47(19) (2004) 4665-76.
- 725 [8] M.H. Steinberg, Sickle cell anemia, the first molecular disease: overview of molecular etiology,
- 726 pathophysiology, and therapeutic approaches, ScientificWorldJournal 8 (2008) 1295-324.
- 727 [9] J.F. Bertles, R. Rabinowitz, J. Döbler, Hemoglobin interaction: modification of solid phase
- 728 composition in the sickling phenomenon, Science 169(3943) (1970) 375-7.
- 729 [10] S. Ballas, Sickle cell pain: Second edition, 2015.
- 730 [11] S.K. Ballas, D.S. Darbari, Review/overview of pain in sickle cell disease, Complement Ther Med 49
- 731 (2020) 102327.
- 732 [12] A. Sanyaolu, E. Agiri, C. Bertram, L. Brookes, J. Choudhury, D. Datt, A. Ibrahim, A. Maciejko, A.
- 733 Mansfield, J. Nkrumah, M. Williams, Current modalities of sickle cell disease management, Blood Sci
- 734 2(4) (2020) 109-116.
- 735 [13] P. Sundd, M.T. Gladwin, E.M. Novelli, Pathophysiology of Sickle Cell Disease, Annu Rev Pathol 14
- 736 (2019) 263-292.
- 737 [14] B.P. Yawn, G.R. Buchanan, A.N. Afenyi-Annan, S.K. Ballas, K.L. Hassell, A.H. James, L. Jordan, S.M.
- 738 Lanzkron, R. Lottenberg, W.J. Savage, P.J. Tanabe, R.E. Ware, M.H. Murad, J.C. Goldsmith, E. Ortiz, R.
- 739 Fulwood, A. Horton, J. John-Sowah, Management of sickle cell disease: summary of the 2014 evidence-
- 740 based report by expert panel members, JAMA 312(10) (2014) 1033-48.
- 741 [15] H. Tran, M. Gupta, K. Gupta, Targeting novel mechanisms of pain in sickle cell disease, Blood
- 742 130(22) (2017) 2377-2385.
- 743 [16] D. Lanznaster, D.R. de Assis, P. Corcia, P.F. Pradat, H. Blasco, Metabolomics Biomarkers: A Strategy
- Toward Therapeutics Improvement in ALS, Front Neurol 9 (2018) 1126.
- 745 [17] X. Hu, M.G. Adebiyi, J. Luo, K. Sun, T.T. Le, Y. Zhang, H. Wu, S. Zhao, H. Karmouty-Quintana, H. Liu,
- A. Huang, Y.E. Wen, O.L. Zaika, M. Mamenko, O.M. Pochynyuk, R.E. Kellems, H.K. Eltzschig, M.R.
- 747 Blackburn, E.T. Walters, D. Huang, H. Hu, Y. Xia, Sustained Elevated Adenosine via ADORA2B Promotes
- 748 Chronic Pain through Neuro-immune Interaction, Cell Rep 16(1) (2016) 106-119.
- 749 [18] Y. Zhang, V. Berka, A. Song, K. Sun, W. Wang, W. Zhang, C. Ning, C. Li, Q. Zhang, M. Bogdanov,
- 750 D.C. Alexander, M.V. Milburn, M.H. Ahmed, H. Lin, M. Idowu, J. Zhang, G.J. Kato, O.Y. Abdulmalik, W.
- 751 Zhang, W. Dowhan, R.E. Kellems, P. Zhang, J. Jin, M. Safo, A.L. Tsai, H.S. Juneja, Y. Xia, Elevated
- 752 sphingosine-1-phosphate promotes sickling and sickle cell disease progression, J Clin Invest 124(6)
- 753 (2014) 2750-61.
- 754 [19] A. Kihara, Y. Igarashi, Production and release of sphingosine 1-phosphate and the phosphorylated
- 755 form of the immunomodulator FTY720, Biochim Biophys Acta 1781(9) (2008) 496-502.
- 756 [20] K. Sun, Y. Zhang, A. D'Alessandro, T. Nemkov, A. Song, H. Wu, H. Liu, M. Adebiyi, A. Huang, Y.E.
- 757 Wen, M.V. Bogdanov, A. Vila, J. O'Brien, R.E. Kellems, W. Dowhan, A.W. Subudhi, S. Jameson-Van
- Houten, C.G. Julian, A.T. Lovering, M. Safo, K.C. Hansen, R.C. Roach, Y. Xia, Sphingosine-1-phosphate
- 759 promotes erythrocyte glycolysis and oxygen release for adaptation to high-altitude hypoxia, Nat
- 760 Commun 7 (2016) 12086.

- 761 [21] K. Sun, A. D'Alessandro, M.H. Ahmed, Y. Zhang, A. Song, T.P. Ko, T. Nemkov, J.A. Reisz, H. Wu, M.
- Adebiyi, Z. Peng, J. Gong, H. Liu, A. Huang, Y.E. Wen, A.Q. Wen, V. Berka, M.V. Bogdanov, O.
- 763 Abdulmalik, L. Han, A.L. Tsai, M. Idowu, H.S. Juneja, R.E. Kellems, W. Dowhan, K.C. Hansen, M.K. Safo,
- 764 Y. Xia, Structural and Functional Insight of Sphingosine 1-Phosphate-Mediated Pathogenic Metabolic
- Reprogramming in Sickle Cell Disease, Sci Rep 7(1) (2017) 15281.
- 766 [22] Y. Xiong, P. Yang, R.L. Proia, T. Hla, Erythrocyte-derived sphingosine 1-phosphate is essential for
- 767 vascular development, J Clin Invest 124(11) (2014) 4823-8.
- 768 [23] H. Wu, M. Bogdanov, Y. Zhang, K. Sun, S. Zhao, A. Song, R. Luo, N.F. Parchim, H. Liu, A. Huang,
- 769 M.G. Adebiyi, J. Jin, D.C. Alexander, M.V. Milburn, M. Idowu, H.S. Juneja, R.E. Kellems, W. Dowhan, Y.
- Xia, Hypoxia-mediated impaired erythrocyte Lands' Cycle is pathogenic for sickle cell disease, Sci Rep
- 771 6 (2016) 29637.
- 772 [24] S.P. Welch, L.J. Sim-Selley, D.E. Selley, Sphingosine-1-phosphate receptors as emerging targets for
- 773 treatment of pain, Biochem Pharmacol 84(12) (2012) 1551-62.
- 774 [25] H. Liu, M. Adebiyi, R.R. Liu, A. Song, J. Manalo, Y.E. Wen, A.Q. Wen, T. Weng, J. Ko, M. Idowu, R.E.
- 775 Kellems, H.K. Eltzschig, M.R. Blackburn, H.S. Juneja, Y. Xia, Elevated ecto-5'-nucleotidase: a missing
- pathogenic factor and new therapeutic target for sickle cell disease, Blood Adv 2(15) (2018) 1957-1968.
- 778 [26] K. Sun, Y. Zhang, M.V. Bogdanov, H. Wu, A. Song, J. Li, W. Dowhan, M. Idowu, H.S. Juneja, J.G.
- 779 Molina, M.R. Blackburn, R.E. Kellems, Y. Xia, Elevated adenosine signaling via adenosine A2B receptor
- induces normal and sickle erythrocyte sphingosine kinase 1 activity, Blood 125(10) (2015) 1643-52.
- 781 [27] Y. Zhang, Y. Dai, J. Wen, W. Zhang, A. Grenz, H. Sun, L. Tao, G. Lu, D.C. Alexander, M.V. Milburn,
- L. Carter-Dawson, D.E. Lewis, W. Zhang, H.K. Eltzschig, R.E. Kellems, M.R. Blackburn, H.S. Juneja, Y. Xia,
- 783 Detrimental effects of adenosine signaling in sickle cell disease, Nat Med 17(1) (2011) 79-86.
- 784 [28] D. Darghouth, B. Koehl, G. Madalinski, J.F. Heilier, P. Bovee, Y. Xu, M.F. Olivier, P. Bartolucci, M.
- 785 Benkerrou, S. Pissard, Y. Colin, F. Galacteros, G. Bosman, C. Junot, P.H. Romeo, Pathophysiology of
- 786 sickle cell disease is mirrored by the red blood cell metabolome, Blood 117(6) (2011) e57-66.
- 787 [29] K.C. Dembele, T. Mintz, C. Veyrat-Durebex, F. Chabrun, S. Chupin, L. Tessier, G. Simard, D. Henrion,
- 788 D. Mirebeau-Prunier, J.M. Chao de la Barca, P.L. Tharaux, P. Reynier, Metabolomic Profiling of Plasma
- 789 and Erythrocytes in Sickle Mice Points to Altered Nociceptive Pathways, Cells 9(6) (2020).
- 790 [30] K.C. Dembele, C. Veyrat-Durebex, G. Aldiouma, S. Chupin, L. Tessier, Y. Goita, M.A. Baraika, M.
- 791 Diallo, B.A. Toure, C. Homedan, D. Mirebeau-Prunier, G. Simard, D. Diallo, B.M. Cisse, P. Reynier, J.M.
- 792 Chao de la Barca, Sickle Cell Disease: Metabolomic Profiles of Vaso-Occlusive Crisis in Plasma and
- 793 Erythrocytes, J Clin Med 9(4) (2020).
- 794 [31] I. Subramanian, S. Verma, S. Kumar, A. Jere, K. Anamika, Multi-omics Data Integration,
- 795 Interpretation, and Its Application, Bioinform Biol Insights 14 (2020) 1177932219899051.
- 796 [32] M.H. Antonelou, A.G. Kriebardis, I.S. Papassideri, Aging and death signalling in mature red cells:
- 797 from basic science to transfusion practice, Blood Transfus 8 Suppl 3(Suppl 3) (2010) s39-47.
- 798 [33] A. Bogdanova, A. Makhro, J. Wang, P. Lipp, L. Kaestner, Calcium in red blood cells-a perilous
- 799 balance, Int J Mol Sci 14(5) (2013) 9848-72.
- 800 [34] R. Hasanato, Alterations in serum levels of copper, zinc, and selenium among children with sickle
- 801 cell anemia, Turk J Med Sci 49(5) (2019) 1287-1291.
- 802 [35] M. Khurana, E.B. Fung, E.P. Vichinsky, E.C. Theil, Dietary nonheme iron is equally bioavailable from
- ferritin or ferrous sulfate in thalassemia intermedia, Pediatr Hematol Oncol 34(8) (2017) 455-467.
- 804 [36] N.A. Sopko, H. Matsui, J.L. Hannan, D. Berkowitz, H.C. Champion, L.L. Hsu, B. Musicki, A.L. Burnett,
- 805 T.J. Bivalacqua, Subacute Hemolysis in Sickle Cell Mice Causes Priapism Secondary to NO Imbalance
- and PDE5 Dysregulation, J Sex Med 12(9) (2015) 1878-85.
- 807 [37] S.C. Wilschefski, M.R. Baxter, Inductively Coupled Plasma Mass Spectrometry: Introduction to
- Analytical Aspects, Clin Biochem Rev 40(3) (2019) 115-133.
- 809 [38] R. Culp-Hill, A.J. Srinivasan, S. Gehrke, R. Kamyszek, A. Ansari, N. Shah, I. Welsby, A. D'Alessandro,
- 810 Effects of red blood cell (RBC) transfusion on sickle cell disease recipient plasma and RBC metabolism,
- 811 Transfusion 58(12) (2018) 2797-2806.

- 812 [39] A. D'Alessandro, S.M. Nouraie, Y. Zhang, F. Cendali, F. Gamboni, J.A. Reisz, X. Zhang, K.W. Bartsch,
- 813 M.D. Galbraith, V.R. Gordeuk, M.T. Gladwin, In vivo evaluation of the effect of sickle cell hemoglobin
- 814 S, C and therapeutic transfusion on erythrocyte metabolism and cardiorenal dysfunction, Am J
- 815 Hematol (2023).
- 816 [40] S.R. Goodman, B.S. Pace, K.C. Hansen, A. D'Alessandro, Y. Xia, O. Daescu, S.J. Glatt, Minireview:
- 817 Multiomic candidate biomarkers for clinical manifestations of sickle cell severity: Early steps to
- 818 precision medicine, Exp Biol Med (Maywood) 241(7) (2016) 772-81.
- 819 [41] A.L. Okwi, M. Ocaido, W. Byarugaba, C.M. Ndugwa, A. Parkes, Sickling and solubility tests and the
- peripheral blood film method for screening for sickle cell disease. [corrected], S Afr Med J 99(12)
- 821 (2009) 887-91.
- 822 [42] T. Sana, S. Fischer, S.J.A.T. Clara, Maximizing metabolite extraction for comprehensive
- metabolomics studies of erythrocytes, (2007) 5989-7407EN.
- 824 [43] Z. Pang, G. Zhou, J. Ewald, L. Chang, O. Hacariz, N. Basu, J. Xia, Using MetaboAnalyst 5.0 for LC-
- HRMS spectra processing, multi-omics integration and covariate adjustment of global metabolomics
- 826 data, Nat Protoc 17(8) (2022) 1735-1761.
- 827 [44] M.A. Rizvi, Z. Hussain, F. Ali, A. Amin, S.H. Mir, G. Rydzek, R.M. Jagtap, S.K. Pardeshi, R.A. Qadri,
- 828 K. Ariga, Bioactive supra decorated thiazolidine-4-carboxylic acid derivatives attenuate cellular
- oxidative stress by enhancing catalase activity, Phys Chem Chem Phys 22(15) (2020) 7942-7951.
- 830 [45] G. Bosman, Disturbed Red Blood Cell Structure and Function: An Exploration of the Role of Red
- 831 Blood Cells in Neurodegeneration, Front Med (Lausanne) 5 (2018) 198.
- 832 [46] E. Szczesny-Malysiak, J. Dybas, A. Blat, K. Bulat, K. Kus, M. Kaczmarska, A. Wajda, K. Malek, S.
- 833 Chlopicki, K.M. Marzec, Irreversible alterations in the hemoglobin structure affect oxygen binding in
- human packed red blood cells, Biochim Biophys Acta Mol Cell Res 1867(11) (2020) 118803.
- 835 [47] G. Tomaiuolo, Biomechanical properties of red blood cells in health and disease towards
- microfluidics, Biomicrofluidics 8(5) (2014) 051501.
- 837 [48] N. Cilek, E. Ugurel, E. Goksel, O. Yalcin, Signaling mechanisms in red blood cells: A view through
- the protein phosphorylation and deformability, J Cell Physiol (2023).
- 839 [49] H. Li, G. Lykotrafitis, Erythrocyte membrane model with explicit description of the lipid bilayer
- and the spectrin network, Biophys J 107(3) (2014) 642-653.
- 841 [50] V. Pretini, M.H. Koenen, L. Kaestner, M. Fens, R.M. Schiffelers, M. Bartels, R. Van Wijk, Red Blood
- 842 Cells: Chasing Interactions, Front Physiol 10 (2019) 945.
- 843 [51] S.L. Spitalnik, D.V. Devine, Translating red cell "omics" into new perspectives in transfusion
- medicine: mining the gems in the data mountains, Transfusion 59(1) (2019) 2-5.
- [52] C. Tang, Q. Meng, K. Zhang, T. Zhan, Q. Zhao, S. Zhang, J. Zhang, Multi-omics analyses of red blood
- cell reveal antioxidation mechanisms associated with hemolytic toxicity of gossypol, Oncotarget 8(61)
- 847 (2017) 103693-103709.
- 848 [53] A. Iolascon, I. Andolfo, R. Russo, Advances in understanding the pathogenesis of red cell
- 849 membrane disorders, Br J Haematol 187(1) (2019) 13-24.
- 850 [54] M. Cascella, S. Vaqar, Hypermagnesemia, StatPearls, Treasure Island (FL), 2023.
- 851 [55] A.O. Olukoga, H.O. Adewoye, R.T. Erasmus, M.A. Adedoyin, Erythrocyte and plasma magnesium
- in sickle-cell anaemia, East Afr Med J 67(5) (1990) 348-54.
- 853 [56] A.O. Olukoga, R.T. Erasmus, H.O. Adewoye, Erythrocyte and plasma magnesium status in
- Nigerians with diabetes mellitus, Ann Clin Biochem 26 (Pt 1) (1989) 74-7.
- 855 [57] C. Antwi-Boasiako, Y.A. Kusi-Mensah, C. Hayfron-Benjamin, R. Aryee, G.B. Dankwah, L.A.
- 856 Kwawukume, E.O. Darkwa, Total Serum Magnesium Levels and Calcium-To-Magnesium Ratio in Sickle
- 857 Cell Disease, Medicina (Kaunas) 55(9) (2019).
- 858 [58] O.O. Yousif, M.K. Hassan, L.M. Al-Naama, Red Blood Cell and Serum Magnesium Levels Among
- 859 Children and Adolescents With Sickle Cell Anemia, Biol Trace Elem Res 186(2) (2018) 295-304.
- 860 [59] B.F. Cameron, P. Smariga, Calcium exchange and calcium-related effects in normal and sickle cell
- anemia erythrocytes, Prog Clin Biol Res 20 (1978) 105-22.

- 862 [60] V. Malinovska, P. Matonoha, V. D'Andrea, L. Malinovsky, A. Zechmeister, The role of calcium in
- the effect of stress hormones, Cas Lek Cesk 130(22-23) (1991) 631-4.
- 864 [61] E. Nur, B.J. Biemond, H.M. Otten, D.P. Brandjes, J.J. Schnog, C.S. Group, Oxidative stress in sickle
- cell disease; pathophysiology and potential implications for disease management, Am J Hematol 86(6)
- 866 (2011) 484-9.
- [62] L. Hertz, R. Huisjes, E. Llaudet-Planas, P. Petkova-Kirova, A. Makhro, J.G. Danielczok, S. Egee, M.
- Del Mar Manu-Pereira, R. van Wijk, J.L. Vives Corrons, A. Bogdanova, L. Kaestner, Is Increased
- 869 Intracellular Calcium in Red Blood Cells a Common Component in the Molecular Mechanism Causing
- 870 Anemia?, Front Physiol 8 (2017) 673.
- 871 [63] C. Brugnara, L. de Franceschi, S.L. Alper, Inhibition of Ca(2+)-dependent K+ transport and cell
- dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives, J Clin Invest 92(1)
- 873 (1993) 520-6.
- 874 [64] C. Brugnara, D.C. Tosteson, Inhibition of K transport by divalent cations in sickle erythrocytes,
- 875 Blood 70(6) (1987) 1810-5.
- 876 [65] E. Nader, M. Romana, P. Connes, The Red Blood Cell-Inflammation Vicious Circle in Sickle Cell
- 877 Disease, Front Immunol 11 (2020) 454.
- 878 [66] V. Barodka, J.G. Mohanty, A.K. Mustafa, L. Santhanam, A. Nyhan, A.K. Bhunia, G. Sikka, D. Nyhan,
- 879 D.E. Berkowitz, J.M. Rifkind, Nitroprusside inhibits calcium-induced impairment of red blood cell
- 880 deformability, Transfusion 54(2) (2014) 434-44.
- 881 [67] C. Antwi-Boasiako, Y.A. Kusi-Mensah, C. Hayfron-Benjamin, R. Aryee, G.B. Dankwah, K.L. Abla, E.
- Owusu Darkwa, F.A. Botchway, E. Sampene-Donkor, Serum Potassium, Sodium, and Chloride Levels in
- Sickle Cell Disease Patients and Healthy Controls: A Case-Control Study at Korle-Bu Teaching Hospital,
- 884 Accra, Biomark Insights 14 (2019) 1177271919873889.
- [68] S. Pandey, A. Sharma, S. Dahia, V. Shah, V. Sharma, R.M. Mishra, S. Pandey, R. Saxena, Biochemical
- indicator of sickle cell disease: preliminary report from India, Indian J Clin Biochem 27(2) (2012) 191-887 5.
- 888 [69] C.T. Noguchi, A.N. Schechter, G.P. Rodgers, Sickle cell disease pathophysiology, Baillieres Clin
- 889 Haematol 6(1) (1993) 57-91.
- 890 [70] D. Manwani, P.S. Frenette, Vaso-occlusion in sickle cell disease: pathophysiology and novel
- 891 targeted therapies, Blood 122(24) (2013) 3892-8.
- 892 [71] J.R. Aluoch, Renal and electrolyte profile in steady state sickle cell disease: observations in
- patients with sickle cell disease in The Netherlands, Trop Geogr Med 41(2) (1989) 128-32.
- 894 [72] J.R. Asirvatham, V. Moses, L. Bjornson, Errors in potassium measurement: a laboratory
- perspective for the clinician, N Am J Med Sci 5(4) (2013) 255-9.
- 896 [73] S. Tomlinson, P.D. Mathialagan, S.K. Maloney, Special K: testing the potassium link between
- radioactive rubidium (86Rb) turnover and metabolic rate, J Exp Biol 217(Pt 7) (2014) 1040-5.
- 898 [74] H.L. Meltzer, R.M. Taylor, S.R. Platmann, R.R. Fieve, Rubidium: a potential modifier of affect and
- 899 behaviour, Nature 223(5203) (1969) 321-2.
- 900 [75] N. Rahimi, M. Hassanipour, F. Yarmohammadi, H. Faghir-Ghanesefat, N. Pourshadi, E.
- 901 Bahramnejad, A.R. Dehpour, Nitric oxide and glutamate are contributors of anti-seizure activity of
- rubidium chloride: A comparison with lithium, Neurosci Lett 708 (2019) 134349.
- 903 [76] L. Xiao, G. Zan, J. Qin, X. Wei, G. Lu, X. Li, H. Zhang, Y. Zou, L. Yang, M. He, Z. Zhang, X. Yang,
- 904 Combined exposure to multiple metals and cognitive function in older adults, Ecotoxicol Environ Saf
- 905 222 (2021) 112465.
- 906 [77] N. Kordjazy, A. Haj-Mirzaian, S. Amiri, S. Ostadhadi, M. Kordjazy, M. Sharifzadeh, A.R. Dehpour,
- 907 Elevated level of nitric oxide mediates the anti-depressant effect of rubidium chloride in mice, Eur J
- 908 Pharmacol 762 (2015) 411-8.
- 909 [78] S. Martin, M.C. Roderick, C. Abel, P. Wolters, M.A. Toledo-Tamula, C. Fitzhugh, M. Hsieh, J. Tisdale,
- 910 Neurocognitive functioning in symptomatic adults with sickle cell disease: A description and
- 911 comparison with unaffected siblings, Neuropsychol Rehabil 30(9) (2020) 1666-1681.

- 912 [79] C.T. Hijmans, K. Fijnvandraat, M.A. Grootenhuis, N. van Geloven, H. Heijboer, M. Peters, J.
- 913 Oosterlaan, Neurocognitive deficits in children with sickle cell disease: a comprehensive profile,
- 914 Pediatr Blood Cancer 56(5) (2011) 783-8.
- 915 [80] S.K. Ballas, Neurocognitive complications of sickle cell anemia in adults, JAMA 303(18) (2010)
- 916 1862-3.
- 917 [81] L.O. Matondo, E. Kija, K.P. Manji, Neurocognitive Functioning among Children with Sickle Cell
- 918 Anemia Attending SCA Clinic at MNH, Dar es Salaam, Tanzania, Neurol Res Int 2020 (2020) 3636547.
- 919 [82] N.S. Green, D. Munube, P. Bangirana, L.R. Buluma, B. Kebirungi, R. Opoka, E. Mupere, P. Kasirye,
- 920 S. Kiguli, A. Birabwa, M.S. Kawooya, S.K. Lubowa, R. Sekibira, E. Kayongo, H. Hume, M. Elkind, W. Peng,
- 921 G. Li, C. Rosano, P. LaRussa, F.J. Minja, A. Boehme, R. Idro, Burden of neurological and neurocognitive
- 922 impairment in pediatric sickle cell anemia in Uganda (BRAIN SAFE): a cross-sectional study, BMC
- 923 Pediatr 19(1) (2019) 381.
- 924 [83] A.A. Hegazy, M.M. Zaher, M.A. Abd El-Hafez, A.A. Morsy, R.A. Saleh, Relation between anemia
- and blood levels of lead, copper, zinc and iron among children, BMC Res Notes 3 (2010) 133.
- 926 [84] M.M. Lubran, Lead toxicity and heme biosynthesis, Ann Clin Lab Sci 10(5) (1980) 402-13.
- 927 [85] J. Schwartz, P.J. Landrigan, E.L. Baker, Jr., W.A. Orenstein, I.H. von Lindern, Lead-induced anemia:
- dose-response relationships and evidence for a threshold, Am J Public Health 80(2) (1990) 165-8.
- 929 [86] C.G. Drossos, K.T. Mavroidis, Z. Papadopoulou-Daifotis, D.N. Michalodimitrakis, L.X. Salamalikis,
- A.K. Gounaris, D.D. Varonos, Environmental lead pollution in Greece, Am Ind Hyg Assoc J 43(10) (1982)
- 931 796-8.
- 932 [87] I.H. Elkhidir, S.S. Ali, W.K. Ali, H.R. Madani, R.A. Basheir, R.M. Altayeb, R.H.S. Shazali, S.
- 933 Fadlelmoula, W.M. Eltayeb, Z.I. Omar, M. Elnil, S.O.O. Mohamed, Zinc, Magnesium, and Copper Levels
- 934 in Patients with Sickle Cell Disease: A Systematic Review and Meta-analysis, Avicenna J Med 12(2)
- 935 (2022) 45-53.
- 936 [88] A. Ece, B.S. Uyanik, A. Iscan, P. Ertan, M.R. Yigitoglu, Increased serum copper and decreased serum
- 237 zinc levels in children with iron deficiency anemia, Biol Trace Elem Res 59(1-3) (1997) 31-9.
- 938 [89] S. Turgut, A. Polat, M. Inan, G. Turgut, G. Emmungil, M. Bican, T.Y. Karakus, O. Genc, Interaction
- between anemia and blood levels of iron, zinc, copper, cadmium and lead in children, Indian J Pediatr
- 940 74(9) (2007) 827-30.
- 941 [90] I.J. Newhouse, D.B. Clement, C. Lai, Effects of iron supplementation and discontinuation on serum
- copper, zinc, calcium, and magnesium levels in women, Med Sci Sports Exerc 25(5) (1993) 562-71.
- 943 [91] H.C. Kim, N.P. Dugan, J.H. Silber, M.B. Martin, E. Schwartz, K. Ohene-Frempong, A.R. Cohen,
- 944 Erythrocytapheresis therapy to reduce iron overload in chronically transfused patients with sickle cell
- 945 disease, Blood 83(4) (1994) 1136-42.

946 [92] K.R. Rao, A.R. Patel, P. McGinnis, M.K. Patel, Iron stores in adults with sickle cell anemia, J Lab Clin

- 947 Med 103(5) (1984) 792-7.
- 948 [93] L. Flohe, W.A. Gunzler, H.H. Schock, Glutathione peroxidase: a selenoenzyme, FEBS Lett 32(1)
- 949 (1973) 132-4.
- 950 [94] J.T. Rotruck, A.L. Pope, H.E. Ganther, A.B. Swanson, D.G. Hafeman, W.G. Hoekstra, Selenium:
- 951 biochemical role as a component of glutathione peroxidase, Science 179(4073) (1973) 588-90.
- 952 [95] S. Li, W. Sun, K. Zhang, J. Zhu, X. Jia, X. Guo, Q. Zhao, C. Tang, J. Yin, J. Zhang, Selenium deficiency
- 953 induces spleen pathological changes in pigs by decreasing selenoprotein expression, evoking oxidative
- 954 stress, and activating inflammation and apoptosis, J Anim Sci Biotechnol 12(1) (2021) 65.
- 955 [96] G.F. Combs, Jr., W.P. Gray, Chemopreventive agents: selenium, Pharmacol Ther 79(3) (1998) 179-
- 956 92.
- 957 [97] R. Irons, B.A. Carlson, D.L. Hatfield, C.D. Davis, Both selenoproteins and low molecular weight
- 958 selenocompounds reduce colon cancer risk in mice with genetically impaired selenoprotein
- 959 expression, J Nutr 136(5) (2006) 1311-7.
- 960 [98] R. Scott, A. MacPherson, R.W. Yates, B. Hussain, J. Dixon, The effect of oral selenium
- supplementation on human sperm motility, Br J Urol 82(1) (1998) 76-80.

- 962 [99] M.P. Look, J.K. Rockstroh, G.S. Rao, K.A. Kreuzer, S. Barton, H. Lemoch, T. Sudhop, J. Hoch, K.
- 963 Stockinger, U. Spengler, T. Sauerbruch, Serum selenium, plasma glutathione (GSH) and erythrocyte
- 964 glutathione peroxidase (GSH-Px)-levels in asymptomatic versus symptomatic human
- immunodeficiency virus-1 (HIV-1)-infection, Eur J Clin Nutr 51(4) (1997) 266-72.
- 966 [100] L. Kiremidjian-Schumacher, M. Roy, Effect of selenium on the immunocompetence of patients
- 967 with head and neck cancer and on adoptive immunotherapy of early and established lesions,
- 968 Biofactors 14(1-4) (2001) 161-8.
- 969 [101] C.R. Morris, J.H. Suh, W. Hagar, S. Larkin, D.A. Bland, M.H. Steinberg, E.P. Vichinsky, M.
- 970 Shigenaga, B. Ames, F.A. Kuypers, E.S. Klings, Erythrocyte glutamine depletion, altered redox
- environment, and pulmonary hypertension in sickle cell disease, Blood 111(1) (2008) 402-10.
- 972 [102] S.R. Goodman, The irreversibly sickled cell: a perspective, Cell Mol Biol (Noisy-le-grand) 50(1)
- 973 (2004) 53-8.
- 974 [103] M. Aslan, D. Thornley-Brown, B.A. Freeman, Reactive species in sickle cell disease, Ann N Y Acad
- 975 Sci 899 (2000) 375-91.
- 976 [104] F.Q. Schafer, G.R. Buettner, Redox environment of the cell as viewed through the redox state of
- 977 the glutathione disulfide/glutathione couple, Free Radic Biol Med 30(11) (2001) 1191-212.
- 978 [105] M.C. Garel, C. Domenget, J. Caburi-Martin, C. Prehu, F. Galacteros, Y. Beuzard, Covalent binding
- of glutathione to hemoglobin. I. Inhibition of hemoglobin S polymerization, J Biol Chem 261(31) (1986)
- 980 14704-9.
- 981 [106] M. Reid, A. Badaloo, T. Forrester, F. Jahoor, In vivo rates of erythrocyte glutathione synthesis in
- 982 adults with sickle cell disease, Am J Physiol Endocrinol Metab 291(1) (2006) E73-9.
- 983 [107] R. Franco, O.J. Schoneveld, A. Pappa, M.I. Panayiotidis, The central role of glutathione in the
- pathophysiology of human diseases, Arch Physiol Biochem 113(4-5) (2007) 234-58.
- 985 [108] J.E. Snoke, K. Bloch, Studies on the mechanism of action of glutathione synthetase, J Biol Chem
- 986 213(2) (1955) 825-35.
- 987 [109] S.C. Rogers, A. Said, D. Corcuera, D. McLaughlin, P. Kell, A. Doctor, Hypoxia limits antioxidant
- 988 capacity in red blood cells by altering glycolytic pathway dominance, FASEB J 23(9) (2009) 3159-70.
- 989 [110] W.G. Siems, O. Sommerburg, T. Grune, Erythrocyte free radical and energy metabolism, Clin
- 990 Nephrol 53(1 Suppl) (2000) S9-17.
- 991 [111] P.S. Low, P. Rathinavelu, M.L. Harrison, Regulation of glycolysis via reversible enzyme binding to
- 992 the membrane protein, band 3, J Biol Chem 268(20) (1993) 14627-31.
- 993 [112] I. Messana, M. Orlando, L. Cassiano, L. Pennacchietti, C. Zuppi, M. Castagnola, B. Giardina,
- 994 Human erythrocyte metabolism is modulated by the O2-linked transition of hemoglobin, FEBS Lett
- 995 390(1) (1996) 25-8.
- 996 [113] D. Sterling, R.A. Reithmeier, J.R. Casey, A transport metabolon. Functional interaction of carbonic
- 997 anhydrase II and chloride/bicarbonate exchangers, J Biol Chem 276(51) (2001) 47886-94.
- 998 [114] L.J. Bruce, R. Beckmann, M.L. Ribeiro, L.L. Peters, J.A. Chasis, J. Delaunay, N. Mohandas, D.J.
- Anstee, M.J. Tanner, A band 3-based macrocomplex of integral and peripheral proteins in the RBC
- 1000 membrane, Blood 101(10) (2003) 4180-8.
- 1001 [115] N.N. Barvitenko, N.C. Adragna, R.E. Weber, Erythrocyte signal transduction pathways, their
- oxygenation dependence and functional significance, Cell Physiol Biochem 15(1-4) (2005) 1-18.
- 1003 [116] M.E. Campanella, H. Chu, P.S. Low, Assembly and regulation of a glycolytic enzyme complex on
- the human erythrocyte membrane, Proc Natl Acad Sci U S A 102(7) (2005) 2402-7.
- 1005 [117] H. Chu, P.S. Low, Mapping of glycolytic enzyme-binding sites on human erythrocyte band 3,
- 1006 Biochem J 400(1) (2006) 143-51.
- 1007 [118] H. Chu, A. Breite, P. Ciraolo, R.S. Franco, P.S. Low, Characterization of the deoxyhemoglobin
- 1008 binding site on human erythrocyte band 3: implications for O2 regulation of erythrocyte properties,
- 1009 Blood 111(2) (2008) 932-8.
- 1010 [119] B.S. Kirby, G. Hanna, H.C. Hendargo, T.J. McMahon, Restoration of intracellular ATP production
- in banked red blood cells improves inducible ATP export and suppresses RBC-endothelial adhesion,
- 1012 Am J Physiol Heart Circ Physiol 307(12) (2014) H1737-44.

- 1013 [120] S.C. Rogers, J.G. Ross, A. d'Avignon, L.B. Gibbons, V. Gazit, M.N. Hassan, D. McLaughlin, S. Griffin,
- 1014 T. Neumayr, M. Debaun, M.R. DeBaun, A. Doctor, Sickle hemoglobin disturbs normal coupling among
- erythrocyte O2 content, glycolysis, and antioxidant capacity, Blood 121(9) (2013) 1651-62.
- 1016 [121] E. Ferru, K. Giger, A. Pantaleo, E. Campanella, J. Grey, K. Ritchie, R. Vono, F. Turrini, P.S. Low,
- 1017 Regulation of membrane-cytoskeletal interactions by tyrosine phosphorylation of erythrocyte band 3,
- 1018 Blood 117(22) (2011) 5998-6006.
- 1019 [122] R.L. Sabina, N.J. Wandersee, C.A. Hillery, Ca2+-CaM activation of AMP deaminase contributes to
- 1020 adenine nucleotide dysregulation and phosphatidylserine externalization in human sickle
- 1021 erythrocytes, Br J Haematol 144(3) (2009) 434-45.
- 1022 [123] M.F. Leal Denis, J.J. Incicco, M.V. Espelt, S.V. Verstraeten, O.P. Pignataro, E.R. Lazarowski, P.J.
- Schwarzbaum, Kinetics of extracellular ATP in mastoparan 7-activated human erythrocytes, Biochim
- 1024 Biophys Acta 1830(10) (2013) 4692-707.
- 1025 [124] B.S. Kirby, M.A. Sparks, E.R. Lazarowski, D.A. Lopez Domowicz, H. Zhu, T.J. McMahon, Pannexin
- 1026 1 channels control the hemodynamic response to hypoxia by regulating O(2)-sensitive extracellular
- 1027 ATP in blood, Am J Physiol Heart Circ Physiol 320(3) (2021) H1055-H1065.
- 1028 [125] H. Zhu, R. Zennadi, B.X. Xu, J.P. Eu, J.A. Torok, M.J. Telen, T.J. McMahon, Impaired adenosine-5'-
- triphosphate release from red blood cells promotes their adhesion to endothelial cells: a mechanism
- of hypoxemia after transfusion, Crit Care Med 39(11) (2011) 2478-86.
- 1031 [126] P. Van der Werf, M. Orlowski, A. Meister, Enzymatic conversion of 5-oxo-L-proline (L-pyrrolidone
- 1032 carboxylate) to L-glutamate coupled with cleavage of adenosine triphosphate to adenosine
- diphosphate, a reaction in the -glutamyl cycle, Proc Natl Acad Sci U S A 68(12) (1971) 2982-5.
- 1034 [127] M. Watanabe, M. Kusano, A. Oikawa, A. Fukushima, M. Noji, K. Saito, Physiological roles of the
- beta-substituted alanine synthase gene family in Arabidopsis, Plant Physiol 146(1) (2008) 310-20.
- 1036 [128] J.J. Abbott, J. Pei, J.L. Ford, Y. Qi, V.N. Grishin, L.A. Pitcher, M.A. Phillips, N.V. Grishin, Structure
- 1037 prediction and active site analysis of the metal binding determinants in gamma -glutamylcysteine
- 1038 synthetase, J Biol Chem 276(45) (2001) 42099-107.
- 1039 [129] P.G. Richman, A. Meister, Regulation of gamma-glutamyl-cysteine synthetase by nonallosteric
- feedback inhibition by glutathione, J Biol Chem 250(4) (1975) 1422-6.
- 1041 [130] A.K. Bachhawat, S. Yadav, The glutathione cycle: Glutathione metabolism beyond the gamma-
- 1042 glutamyl cycle, IUBMB Life 70(7) (2018) 585-592.
- 1043 [131] Z. He, X. Sun, S. Wang, D. Bai, X. Zhao, Y. Han, P. Hao, X.S. Liu, Ggct (gamma-glutamyl
- 1044 cyclotransferase) plays an important role in erythrocyte antioxidant defense and red blood cell
- 1045 survival, Br J Haematol 195(2) (2021) 267-275.
- 1046 [132] S. Kageyama, E. Hanada, H. Ii, K. Tomita, T. Yoshiki, A. Kawauchi, Gamma-
- 1047 Glutamylcyclotransferase: A Novel Target Molecule for Cancer Diagnosis and Treatment, Biomed Res
- 1048 Int 2015 (2015) 345219.

List of Abbreviation

- 1068 SCD, Sickle cell disease
- 1069 ICP-MS, Inductively coupled plasma mass spectrometry
- 1070 LC-MS, Liquid chromatography-mass spectrometry
- 1071 RBC, Red blood cell

- 1072 SS-RBCs, sickle shaped RBCs (SS-RBCs)
- 1073 WHO, World health organisation
- 1074 VOC, Vaso-occlusive crisis
- 1075 Hb, hemoglobin
- 1076 HbA, adult hemoglobin
- 1077 HbS, sickle cell hemoglobin
- 1078 HbF, Fetal hemoglobin
- 1079 VOC, Vaso-Occlusive crisis
- 1080 QoL, quality of life
- 1081 HSCT, hematopoietic stem cell transplantation
- 1082 O₂, Oxygen
- 1083 HbS-O₂, Oxygenated sickle hemoglobin
- p50, the pressure at which hemoglobin is 50% saturated
- 1085 ROS, reactive oxygen species
- 1086 pO₂, partial pressure of oxygen
- 1087 Tg, Transgenic
- 1088 ADORA2B, Adenosine A2b Receptor
- 1089 S1P, sphingosine-1-phosphate (S1P)
- 1090 EMP, Embden Meyerhoff pathway
- 1091 HMP, Hexose monophosphate pathway
- 1092 2, 3-DPG, 2,3 Diphosphoglyceric Acid
- 1093 2, 3-BPG, 2, 3 Bisphosphoglyceric acid
- 1094 S1PR1, S1P receptor 1
- 1095 SphK1, Sphingosine Kinase-1
- 1096 ADA, Adenosine deaminase deficiency
- 1097 PEG-ADA, Polyethylene glycol-modified adenosine deaminase
- 1098 CD73, ecto-5'-nucleotidase
- 1099 CAR, Central African Republic (BAN or CAR)
- 1100 CAM, Cameroon
- 1101 BEN, Benin
- 1102 SEN, Senegal
- 1103 ARB/AI, Arab-Indian
- 1104 HbSS, Homozygous sickle cell disease/Sickle cell disease
- 1105 HbAS, Hetrozygous sickle cell trait/ Sickle cell trait
- 1106 HbAA, Homozygous normal/ Healthy control
- 1107 HC, Healthy control
- 1108 CBC, Complete blood count
- 1109 PCR, Polymerase chain reaction
- 1110 HPLC. High performance liquid chromatography
- 1111 HCD, Higher-energy C-trap dissociation
- 1112 OPLS-DA, orthogonal projections to latent structures discriminant analysis
- 1113 FDR, false discovery rate
- 1114 PCA, principal component analysis
- 1115 SVM, Linear support vector machine

- 1116 MCCV, Monte-Carlo cross-validation
- 1117 ROC, receiver operating characteristic
- 1118 AUROC, Area under ROC
- 1119 H₂O₂, Hydrogen peroxide
- 1120 HNO₃, Nitric acid
- 1121 N₂, Nitrogen
- 1122 ²⁴Mg, Magnesium
- 1123 ⁴⁴Ca, Calcium
- 1124 ⁵⁷Fe, Iron
- 1125 ⁶³Cu, Copper
- 1126 ⁶⁶Zn, Zinc
- 1127 ⁷⁷Se, Selenium
- 1128 ⁸⁵Rb, Rubidium
- 1129 ²⁰⁸Pb, Lead
- 1130 ³⁹K, Potassium
- 1131 Hb-O₂, oxyhemoglobin
- 1132 KCC1/3/4, K-Cl co-transporter
- 1133 IQ, Intelligent quotient,
- 1134 BLL, Blood lead level
- 1135 HCT, Hematocrit
- 1136 HGB, Hemoglobin (g/dl)
- 1137 MCHC, Mean corpuscular hemoglobin concentration
- 1138 NADPH, Nicotinamide adenine dinucleotide phosphate
- 1139 GSH, reduced glutathione
- 1140 GSSG, oxidized (GSSG)
- 1141 G-Hb, glutathiol-hemoglobin
- 1142 DPT, dipeptidases (DPT)
- 1143 GGCS, gamma-glutamylcysteine synthetase (G-GCS)
- 1144 γ-GCT/GGCT, gamma-glutamyl cyclotransferase (G-GCT)
- 1145 OXP, oxoprolinase
- 1146 GGT, gamma-glutamyl transpeptidase
- 1147 ATP, Adenosine triphosphate
- 1148 cdB3, Band 3

- 1149 γ-GCS/GGCS, gamma-glutamylcysteine synthetase
- 1150 GS, GSH sythetase